Codiak BioSciences, Inc. expected to post a loss of 82 cents a share - Earnings Preview

Codiak BioSciences,.

01/11/2022 02:08

* Codiak BioSciences, Inc.  CDAK.OQ   CDAK.O  is expected
to show
a fall in quarterly revenue when it reports  results on November
2 (estimated). 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 49.2% decrease in revenue to $587.67 thousand from $1.16
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Codiak BioSciences,
Inc.
is for a loss of 82 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Codiak
BioSciences, Inc. is $7​, above​ its last closing price
of $0.71. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.80       -0.84      -0.30     Beat    64.1
 Mar. 31 2022  -0.88       -0.89      -0.36     Beat    59.7
 Dec. 31 2021  -0.98       -0.94      -0.74     Beat    21.6​
 Sep. 30 2021  -0.94       -0.94      -0.97     Missed  -2.6
 ​​Jun.        -1.04       -1.05      -0.99     Beat    5.4
 30 2021                                                
 Mar. 31 2021  -1.10       -1.09      -0.51     Beat    53.4​
 Dec. 31 2020  -1.82       -1.54      -1.14     Beat    25.8
 Sep. 30 2020  -5.51       -5.50      -12.83    Missed  -133.4
 This summary was machine generated November 1 at 02:08 GMT.  All
figures in US dollars  unless otherwise stated